Cardiac Dimensions, a Kirkland, WA-based developer of treatment modalities to address heart failure and related cardiovascular conditions, raised $35M in Series D funding.
The round was co-led by Horizon 3 Healthcare and an undisclosed strategic investor, with participation from Arboretum Ventures, Hostplus, EQT Life Sciences, Lumira Ventures, and M. H. Carnegie & Co.
The company intends to use the funds to enroll the U.S. EMPOWER pivotal study of the Carillon therapy, which commenced late last summer and includes leading centers such as the Cleveland Clinic, Columbia University Medical Center, and Ronald Reagan UCLA Medical Center, and expand sales of the Carillon device in several European countries where it has full reimbursement.
Led by CEO Rick Wypych, Cardiac Dimensions is a developer of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company’s lead product – the Carillon Mitral Contour System® – uses a minimally-invasive approach designed to restore natural mitral valve function without damaging the mitral valve leaflets. In a short, simple procedure, the Carillon® device is intended to induce favorable remodeling while reducing mitral regurgitation (MR), improve patient quality of life, and extend survival for a broad swath of patients, including those with earlier-stage MR.
Cardiac Dimensions has operations in Kirkland, Washington, Sydney, Australia and Frankfurt, Germany.
FinSMEs
05/01/2023